anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The main objective is to prospectively evaluate long-term efficiency of bariatric surgery in terms of weight loss. Moreover, this cohort wants to assess the long-term effectiveness of bariatric surgery on comorbidities and quality of life, the medical and economic impact of bariatric surgery (before-after comparison using data from health insurance), estimates the incidence of mortality and morbidity of bariatric surgery and to finish describe the evolution of patients in case of new-surgery. From a methodological point of view, the Obesity cohort is a prospective cohort study, single-center, open, with aftercare performed during life of patients. The number of inclusions is to 1500 patients. After surgery , patients will be followed at least 4 visits the first year and at least 2 visits a year then. The recommendations of the french health ministry (HAS), the frequency of visits may be increased according to the patient's progress. Follow-up visits of patients after bariatric surgery will be performed by physicians or surgeons of the multidisciplinary team responsible for the care of the patient (digestive and reconstructive surgery, anesthesiology, endocrinology, medical imaging, gastroenterology, immunology and physiology) . It will be insured for life, obesity is a chronic disease and because of the risk of late complications.
The present invention relates to a sodium ferulate orally disintegrating tablet and a preparation process thereof. The tablet has the effects of resisting oxidation, eliminating free radical, preventing the cytomembrane from oxidation and inhibiting platelet aggregation and thrombus formation, and the tablet is used for treating atherosclerosis, embolism vasculitis, acute cerebral embolism, migraine, etc. in clinic. Sodium ferulate is used as a raw material; filling agents, disintegrating agents, corrigents, flow aid, lubricating agents, etc. are used as auxiliary materials; adhesives or coating materials can also be used in different situations; appropriate quantity of effervescent agents can be added conditionally; the orally disintegrating tablet is prepared by a specific preparation method and obtained after tabletting by a tabletting machine. The orally disintegrating tablet of the present invention has the characteristics of good friability, rapid disintegration, good taste, no gravel feel, no need of specific production condition, low production cost, convenient carry, storage, transportation and use, etc.; patients can take medicine without water, and the medicine can take effect quickly; therefore, the present invention improves patient's compliance and enhances the curative effect of the medicine.
The invention relates to a traditional Chinese medicine extractive cataplasm for treating liver ascites and a preparation method thereof and belongs to the technical field of traditional Chinese medicine. The traditional Chinese medicine extractive cataplasm for treating liver ascites consists of sodium polyacrylate, aluminium hydroxide, propanetriol, citric acid, a penetration-promoting agent, acinnamon extractive and an extractive from notoginseng, euphorbia kansui and cinnamon dregs. System one is obtained by mixing and stirring well sodium polyacrylate, aluminium hydroxide, the cinnamon extractive and the penetration-promoting agent while System two is obtained by adding the extractive from the compound of notoginseng, euphorbia kansui and cinnamon into the citric acid and stirring to dissolution. System two is added into System one many times with equal volume, well mixed, coated, placed, dried, covered with a cover lining and then the traditional Chinese medicine extractive cataplasm for treating liver ascites is obtained. The traditional Chinese medicine extractive cataplasm for treating liver ascites has a tonifying effect on the qi-blood deficiency caused by ascites due to cirrhosis and the rooted deficiency due to the phlegm stagnation of qi, blood and water. In addition, the traditional Chinese medicine extractive cataplasm for treating liver ascites discards glutin adopted in a conventional preparation of cataplasm but adds in a cross linker and a cross-linking regulator instead, thereby increasing the glutinosity and cohesive force.
SCOPE: The gut microbiota plays a role in fat accumulation and energy homeostasis. Therefore, probiotic supplementation may improve metabolic parameters and control body weight.
METHODS AND RESULTS: In this study, mice are fed either a high-fat diet (HFD) or an HFD supplemented with oral gavage of a mixture of three probiotic strains, Bifidobacterium lactis Lafti B94, Lactobacillus plantarum HA-119, and Lactobacillus helveticus Lafti L10 for 7 weeks. It finds that probiotic supplementation modulates body weight gain, food energy efficiency, and fat accumulation caused by the HFD. This probiotic mix prevents liver damage and lipid metabolic disorders in HFD-fed obese mice. The probiotic supplementation significantly downregulates the expression of the proinflammatory cytokines interleukin-1β, tumor necrosis factor-α, and malondialdehyde (MDA) in the liver and upregulated catalase (CAT), superoxide dismutase (SOD), and nuclear respiratory factor 1 (Nrf1) expression. Mice supplemented with the probiotic mix also show different microbiota compositions, with an increase in Clostridia_UCG-014 and Lachnospiraceae_nk4a136_group and a decrease in the Dubosiella genus compared with those in mice fed only an HFD. Finally, the amounts of fecal pentanoic acid and the three bile acid species increase in mice with probiotic supplementation.
CONCLUSION: Treatment with a combination of a mixture of three probiotic strains, B. lactis Lafti B94, L. plantarum HA-119, and L. helveticus Lafti L10 for 7 weeks, ameliorates the effects of HFD induced obesity in mice.
Obesity stands as a pervasive global public health issue, posing a formidable threat to human well-being as its prevalence continues to surge year by year. Presently, pharmacological treatment remains the favored adjunct strategy for addressing obesity. However, conventional delivery methods suffer from low bioavailability and the potential for side effects, underscoring the pressing need for more efficient and targeted delivery approaches. Recent research has delved extensively into emerging drug delivery systems employing polymers as carriers, with numerous preclinical studies contributing to the growing body of knowledge. This review concentrates on the utilization of natural polymers as drug delivery systems for the treatment of obesity, encompassing recent advancements in both natural and synthetic polymers. The comprehensive exploration includes an analysis of the advantages and disadvantages associated with these polymer carriers. The examination of these characteristics provides valuable insights into potential future developments in the field of drug delivery for obesity treatment.
<P>PROBLEM TO BE SOLVED: To provide a culture liquid produced by using a natural material, having functions such as humectant, antibacterial, antiinflammatory, oxidation and antiputrefaction actions, and applicable to foods and cosmetics, and provide a method for producing the liquid and a face lotion produced by using the liquid.  <P>SOLUTION: A tree fern and gingko extract produced by extraction-treating leaves of tree fern and gingko is mixed with humus and water and a solid component is separated after the culture for a prescribed period. An alkaline ion water is used as the water. The culturing period is set to ≥30 days. The face lotion is produced by compounding the culture liquid.  <P>COPYRIGHT: (C)2004,JPO
The present invention relates to genetic engineering. An endogenous small plasmid pPBS1 is extracted from plectonema boryanum to construct a blue algae shuttle expression vector pPKE2. A replication origin of a colibacillus source and a blue algae source plasmid exists in the genetic engineering. A selective marker, a promotor, multi-cloning sites and a terminator existing in the genetic engineering can be used as a recipient bacterium expressed by an exogenous gene in the blue algae. A thymosin alpha1 gene (Talpha1) as a target gene and an ubiquitin gene are fused and then are inserted into the multi-cloning sites of the expression vector pPKE2 to obtain a recombinant plasmid containing the target gene Talpha1 in the present invention. Simultaneously, the recombinant plasmid is transformed into Synechococcussp PCC7942. A Talpha1 expression product is verified by the southern hybridization and is detected by a western blotting method.
All patients who will receive 12 weeks of treatment with telaprevir 750 mg q8h except for patients on efavirenz will receive 1125 mg every 8 hours (q8h) in combination with Pegylated-Interferon-alfa-2a (Peg-IFN-alfa-2a) 180 μg/week and RBV 800 mg/day. At Week 12, telaprevir dosing will end and the patients will continue on Peg-IFN-alfa-2a and RBV.
FIELD: hair care facilities. SUBSTANCE: aerosol device for fixing and/or keeping hair style comprises cosmetic composition for hair including at least one specific silicon acrylate copolymer. Method for keeping and making hair style involves using said aerosol device. Method and device allow high-quality spray of aerosol composition to be provided with regard to spraying capacity and drop size. EFFECT: improved quality of cosmetic composition and device, increased efficiency and reduced consumption of composition due to reduced dissipation thereof during spraying. 12 cl
An individually tailored voice therapy where the order and length of voice treatment methods will depend on the nature of each subject's voice problems. The intervention will take eight weeks and average of eight sessions (a' 45 min).
The invention relates to an anti-HIV-1-virus tuberculosis gene vaccine composed of a vector. An exogenous target gene is inserted into the vector. The exogenous target gene comprises a gene of a capsid protein p24 sourced from a HIV-1NL4-3 strain. T cell epitope polypeptide genes MPT6476-84, Ag85A242-250, Ag85B184-192 and TB10.474-82 from mycobacterium tuberculosis antigen are embedded in the capsid protein p24 gene. The invention also provides a preparation method and an application of the anti-HIV-1-virus tuberculosis gene vaccine. When the gene vaccine is used in intramuscular injection for immunizing mice, Th1-type immune response and specific killing response secreting high-level IFNgamma aiming at tuberculosis antigens can be induced, and specific serum IgG and T-cell immune response aiming at HIV-1 antigen p24 can be induced. Therefore, the vaccine can be used for preventing tuberculosis and inhibiting HIV.
FIELD: medicine. SUBSTANCE: method involves MAKING extremity amputation according to method indicated fro the patient. Nerve trunk is selected and the nerve is laid at the distance of 4.0-7.0 cm proximal relative to amputation level using injection needle and anesthesia is done at the whole length of the injection needle in prolonged mode in proximal direction with lidocaine solution having 3-5 adrenaline solution drops. Dense creeping intraneural infiltrate is created. The injection needle is pulled by 1.0-1.5 cm. The nerve is temporarily ligated 0.5 cm in proximal direction with respect to the marked level for truncating nerve with strong catgut ligature in one simple angle. The ligature ends are tightened. 5.0-8.0 ml of 40-45% ethyl alcohol solution are injected into the nerve in bolus mode. The nerve trunk is truncated in distal position relative to the ligature applied to the nerve using sharp shaving blade at 0.5 cm large distance from it. 4.0-6.0 cm long fragment is cut out from deep large diameter vein and put over the nerve stump as an envelope. The end with adjacent epineurium is coagulated with light radiation. The nerve end surface with adjacent epineurium is treated with high intensity defocused laser radiation of 230-390 W/cm 2  power and the laser beam is moved at 0.5 cm/s speed. The upper slice of the autovein fragment is attached to the epineurium with four thin catgut ligatures. The nerve stump is covered with autovein fragment at the level of thick catgut ligature used for stump edge finishing by applying surgical knot. A part of 0.4-0.6 cm long venous fragment is retained in distal position relative to the thick catgut ligature. EFFECT: enhanced effectiveness and quality of nerve stump treatment; prevented postoperative complications.
Selection of embryos are based on blastocyst morphology criteria on day 5. A maximum of 2 embryos will be transferred for each treatment cycle.
Essential Oil inhalation patches are a nonpharmacological option that is worn by the nursing staff on an inpatient medical-surgical unit to determine the efficacy of patch on staff perceived stress \& burn-out levels. Each participant will wear a new patch during six work shifts. Location is on chest or the ID badge area where it can be easily accessed to. The patch provides up to 8 hours of aromatic support. The patches use a unique patented technology that slows the release of the aromatic molecules while maintaining the purity and vitality of the essential oil. The FDA approved medical adhesive patches are roughly 1x1" in size, and are inhalation only- no contact of essential oils on skin. The patch is portable and discreet. No overwhelming aroma for others. The patch has directions for use on package with an expiration date. Used for a non-specific purpose for stress reduction environment for this study.
NEW MATERIAL:A compound of formulaI[A is (S)-asparagine residue of formula II; (R)-asparagine residue of formula III or (R)-arginine residue of formula IV]. EXAMPLE:(2S,3R)-3-Amino-2-hydroxy-4-phenylbutanoyl-(S)-leucyl-(S)-aspa ragine. USE:A cancer immunotherapeutic and infection protecting agent, having inhibitory action on aminopeptidase and activating action on cellular immunity, and capable of enhancing the cellular immunity in a small dose. PROCESS:Bestatin of formula V is condensed with an amino acid of formula VI [R is carbamoylmethyl of H2NCOCH2-, etc.; * is the configuration of (S) or (R)]by the carbodiimide method, etc. to give the compound of formulaI. A solvent usually used in forming peptide bonds can be used as the solvent used for the condensation.
The invention discloses traditional Chinese medicine composition for preventing and treating restenosis after coronary stenting. A traditional Chinese medicine preparation is prepared from raw materials as follows: oplopanax elatus, red fruit ginseng, roots of Ficus beecheyana Hook. et Arn., twocolor magnoliavine roots and stems, roots of garden lovage, Cinnamomum burmannii Bl., leaves or roots of Styrax suberifolium Hook. et Arn., flowers of Aglaia odorata Lour., Polygala arillata Buch.Ham., winged euonymus twigs, Dichocarpum auriculatum and martianus dermestoides. The provided traditional Chinese medicine composition for preventing and treating restenosis after coronary stenting can relieve the symptoms and reduces restenosis, the treatment cost is reduced, the life quality of a patient is improved, and the compliance of the patient is good. Water decoction of the provided traditional Chinese medicine composition for preventing and treating restenosis after coronary stenting is used for treating 34 patients, the restenosis rate of the treatment group is 11.76% after treatment for six months, the restenosis rate of a contrast group is 35.29%, and the restenosis rate of the treatment group is remarkably lower than that of the contrast group.
PURPOSE:To provide an anticoagulant peptide exhibiting a fibrin coagulation inhibitory activity and useful for prevention and improvement of thrombosis and to provide a medicine containing this peptide as the active component and capable of improving thrombosis. CONSTITUTION:An anticoagulant peptide is a peptide composed of L-amino acids and represented by a following general formula or its salt; Gly-Pro-Arg-Y- Z. (Y is Gly or Pro. Z is Pro, Pro-Pro, Ala, Gly, Arg, etc.). This peptide exhibits a high fibrin coagulation inhibitory activity and a high safety because of its structure similar to a fragment of a biological polymer, collagen. Accordingly, this peptide is useful as a medicine for improvement of thrombosis or an anti- thrombogenic food.
PURPOSE: Surgical site infections pose a significant challenge for medical services. Systemic antibiotics may be insufficient in preventing bacterial biofilm development. With the local administration of antibiotics, it is easier to minimize possible complications, achieve drugs' higher concentration at the injured site, as well as provide their more sustained release. Therefore, the main objective of the proposed herein studies was the fabrication and characterization of innovative hydrogel-based composites for local vancomycin (VAN) therapy.
METHODS: Presented systems are composed of ionically gelled chitosan particles loaded with vancomycin, embedded into biomimetic collagen/chitosan/hyaluronic acid-based hydrogels crosslinked with genipin and freeze-dried to serve in a flake/disc-like form. VAN-loaded carriers were characterized for their size, stability, and encapsulation efficiency (EE) using dynamic light scattering technique, zeta potential measurements, and UV-Vis spectroscopy, respectively. The synthesized composites were tested in terms of their physicochemical and biological features.
RESULTS: Spherical structures with sizes of about 200 nm and encapsulation efficiencies reaching values of approximately 60% were obtained. It was found that the resulting particles exhibit stability over time. The antibacterial activity of the developed materials against Staphylococcus aureus was established. Moreover, in vitro cell culture study revealed that the surfaces of all prepared systems are biocompatible as they supported the proliferation and adhesion of the model MG-63 cells. In addition, we have demonstrated significantly prolonged VAN release while minimizing the initial burst effect for the composites compared to bare nanoparticles and verified their desired physicochemical features during swellability, and degradation experiments.
CONCLUSION: It is expected that the developed herein system will enable direct delivery of the antibiotic at an exposed to infections surgical site, providing drugs sustained release and thus will reduce the risk of systemic toxicity. This strategy would both inhibit biofilm formation and accelerate the healing process.
Subjects will receive an inhaled single dose of GSK2292767 50 µg in Period 1, GSK2292767 200 µg in Period 2, and placebo in Period 3. There will be a washout of approximately 4 weeks between doses.
BACKGROUND: After submaximal exercise, blood values of eventing horses show physiological reactions.
OBJECTIVES: This prospective longitudinal study investigated blood parameters in 20 elite eventing horses before and after two-four-star cross-country rides.
METHODS: Using a mixed model adjusting for plasma volume shift, we assessed exercise-dependent parameters and compared blood values with reference ranges for healthy horses at rest.
RESULTS: Following exercise, cortisol, triiodothyronine (T3) and thyroxine (T4) showed short-term increases, and superoxide-dismutase showed a small short-term increase. Hepatic values showed short-term (haemoglobin [HGB], globulins) or sustained increases (bilirubin, glutamate dehydrogenase, alanine aminotransferase). Digestion-related parameters showed small short-term increases (α-amylase, triglycerides) or decreases (cholesterol, DGGR-lipase), apparent through plasma shift adjustment. Zinc decreased in the short term, and iron showed a delayed decrease. White blood cell count increased persistently after training, whereas serum amyloid A remained unchanged.
CONCLUSIONS: Exercised eventing horses had consistently elevated HGB and cortisol levels 10 and 30 min after submaximal exercise, exceeding the reference ranges for healthy horses at rest. Exercise activates the hypothalamic-pituitary-adrenocortical and hypothalamic-pituitary-thyroid axes. Antioxidant activity was observed. Increased energy requirements led to the mobilization of energy reserves, and a sustained increase in liver enzymes indicated hepatocellular injury. Mild haemolysis suggested increased muscle metabolism, whereas signs of inflammation were subtle. Further research is needed to identify which horses deviate from mean values.
Although whole exome sequencing (WES) was first used for identification of the genetic cause of a disease only in 2009 and whole genome sequencing (WGS) in 2010, and questions remain about their performance as clinical tests, they are already being offered to patients and doctors as a clinical test by several laboratories certified by the US government (14 labs for WES and 5 labs for WGS). The results from WES and WGS can be complex and confusing, even for doctors and scientists who work with this technology on a daily basis; for patients, the process of deciding whether to have WES or WGS testing, undergoing the testing, receiving the results, and trying to use the results for further decision-making could be quite stressful. Currently, this process occurs in an unstandardized fashion, with some patients receiving extensive education and counseling, and others receiving almost none. There is a critical need to identify patient needs and desires in this area, and to develop strategies to satisfy them. The primary goal of this project is to gain knowledge about how patients undergoing prenatal diagnosis for a fetal abnormality understand and react to WGS testing, so that we can develop a more ethical and responsible approach to patient education, counseling, and return of results for patients . In order to do this, we need to evaluate parents' understanding of the utility and limitations of the technology, parents' preferences regarding the types of results they want to receive, and the psychological impact of receiving results from this technology. We will enroll 30 families consisting of a woman carrying a fetus with a major abnormality identified by ultrasound, and the father of the fetus, who have opted for amniocentesis for standard prenatal diagnostic testing (karyotyping, fluorescence in situ hybridization (FISH) and/or microarray testing). Half of the families will serve as controls, who will only have standard prenatal diagnostic testing. For the other half of the families, WGS will be performed in addition to standard diagnostic testing. For all 30 cases, we will perform psychosocial evaluations (including assessments of the subjects' mood, understanding of the technology and preferences for return of results) at the time of enrollment, at the time of return of CLIA-certified genetic testing results (karyotype, FISH, microarray, and/or WGS), and after completion of the pregnancy. In this way, we will learn whether participants are receiving adequate education about next-generation sequencing to make informed choices, what the range of preferences are for return of results in a prenatal population (and whether this changes when new methods for prenatal diagnosis are employed), and whether the use of WGS imposes additional psychological stress compared to standard prenatal diagnostic tests. This study will be carried out in a stepwise and carefully monitored environment, with progress overseen by an Independent Data Monitoring Committee in order to maximize the knowledge gained while minimizing potential harms.